Today, OGT announced the launch of its newly updated NGS SureSeq CLL + CNV V3 Panel which further incorporates the company’s sensitive proprietary bait designs to offer more expansive coverage of disease-associated genes.
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).
Editor Rebekah Jordan spoke to Kevin Kreutter, Ph.D., senior vice president, Drug Discovery, Empress Therapeutics about how the company is using AI to analyse genetic data, to accelerate and refine small molecule drug discovery.
Pheast Therapeutics announced the presentation of new preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage "don't eat me" signal on cancer cells.
PacBio announced the Vega system, the company’s first benchtop long-read sequencing platform, delivering all the functionality of the Revio system into a compact, lower-throughput benchtop platform.
Sonrai is working to bring its innovative cloud-based AI technology to the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital (MGH), enabling vast and complex data for more meaningful insights.
University of Birmingham Enterprise announces the launch of Biocell Energetics, to provide profiling and testing services that assess, in real-time, how living cells produce energy.
Mestag Therapeutics announced that it has entered into a license and collaboration agreement with MSD to identify novel targets for the development of therapies against inflammatory diseases.
A peer reviewed study published in Frontiers in Neuroscience has shown that Ellorarxine, a novel drug compound developed by biotech spinout Nevrargenics, has shown a robust neuroprotective effect in cultured cells and reaches its target in animals.
